Introduction
============

Squamous cell carcinoma (SCC) represents the vast majority (90%) of malignant oral neoplasms ([@b1-ol-0-0-4588]). Recent figures on SCCs emphasise the growing incidence rate and the limited and often unsatisfying treatment options ([@b2-ol-0-0-4588],[@b3-ol-0-0-4588]). Treatments are known to be unsatisfactory in terms of survival rates, as local and regional metastases occur frequently even in small tumors ([@b4-ol-0-0-4588]). The harm caused by agents, such as alcohol or tobacco, is important in cancerization, and may be responsible for the formation of secondary tumors and disease recurrence ([@b5-ol-0-0-4588],[@b6-ol-0-0-4588]). A detailed knowledge concerning the molecular mechanisms in the pathogenesis and progression of SCCs, and its precursor lesions, is required to aid in the improvement of therapeutics and incidence rates.

Cytokeratins (CKs) are major intermediate filaments in squamous epithelium and are critical in cell stabilization, shape, intracellular signalling and transport ([@b7-ol-0-0-4588],[@b8-ol-0-0-4588]). CK expression is a hallmark of tumor progression. Previous studies demonstrated that the expression of high-molecular weight CK8 and 18 was associated with dysplasia grades of tumor precursor lesions and an unfavorable prognosis for patients with SCCs ([@b9-ol-0-0-4588],[@b10-ol-0-0-4588]). Other studies had similar observations ([@b11-ol-0-0-4588],[@b12-ol-0-0-4588]). Loss of CK8 phosphorylation initiates an increased cell migration and tumor spread in SCCs, whereas loss of CK8 and 18 led to alterations in α6β4-integrin mediated signalling and decreased neoplastic progression ([@b11-ol-0-0-4588],[@b13-ol-0-0-4588],[@b14-ol-0-0-4588]). In addition, an increased expression of low-molecular weight CK19 was associated with high-grade dysplasia and squamous intraepithelial neoplasia and a decreased survival rate of patients with SCCs ([@b9-ol-0-0-4588],[@b15-ol-0-0-4588]). CK19 expression is not observed in benign or hyperplastic regions of keratinized oral epithelium ([@b10-ol-0-0-4588],[@b15-ol-0-0-4588]). Additionally, the expression of CKs interferes with a multitude of other intracellular regulation pathways, including numerous kinases, receptors and apoptotic proteins ([@b16-ol-0-0-4588]); therefore, the effects of CKs are highly complex.

The present study demonstrates the frequencies of low and high molecular weight CKs in SCCs of the oral cavity with respect to their anatomical sublocalization, and evaluates the coexpression of a multitude of proteins involved in various cellular regulatory pathways. The aim of the present study was to elucidate the complex interaction between CK expression patterns and alterations in other cellular pathways. The present results revealed the existence of two pathogenetic pathways in the evolution of oral SCC, which are associated with the preferential expression of low- and high-molecular weight CKs.

Patients and methods
====================

### Patients

All patients eligible for the current study presented with histologically confirmed oral SCC, and underwent surgery at the University Hospital Muenster (Münster, Germany) between January 1988 and December 2000. Data collection and evaluation was conducted in compliance with the current version of the Declaration of Helsinki and the International Conference for Harmonization of Good Clinical Practice ([@b17-ol-0-0-4588],[@b18-ol-0-0-4588]). All data and specimens were evaluated after obtaining written informed consent from the patient and ethical approval from the Ethical Commission of the Medical Association Westfalen-Lippe and the Faculty of Medicine of the Westphalian Wilhelms-University Muenster. The tumor samples were formalin-fixed, archival paraffin-embedded tissues from 193 patients (154 men; 39 women) with primary oral SCC. The patients\' mean age was 59 years (range, 31--90 years) ([Table I](#tI-ol-0-0-4588){ref-type="table"}). Information regarding clinicopathological details and treatment modalities of this tumor series is described in previous studies ([@b9-ol-0-0-4588],[@b10-ol-0-0-4588],[@b19-ol-0-0-4588]--[@b21-ol-0-0-4588]). According to the Union for International Cancer Control guidelines ([@b22-ol-0-0-4588]), all the SCCs were classified post-surgery by the tumor-node-metastasis system (T1=96, T2=82, T3-4=15; N0=136, N\>0=57). All patients attended a follow-up program with clinical evaluation for 4--181 months. As described in previous studies ([@b9-ol-0-0-4588],[@b10-ol-0-0-4588],[@b19-ol-0-0-4588]--[@b21-ol-0-0-4588]), the time of survival was defined as the time between the date of surgery and the date of histopathologically proven tumor recurrence, metastatic disease, death associated with the disease or a tumor-free follow-up period of 60 months. Patients who missed regular attendance at follow-up were excluded from the present study.

### Immunohistochemistry

To provide equal assessment conditions, all tumor samples were analyzed by tissue microarray (TMA) and immunohistochemistry. As previously described ([@b23-ol-0-0-4588]), all TMAs were used according to a standard procedure. For the TMA block construction, two punch biopsies (diameter, 0.6 mm) were extracted from formalin-fixed, paraffin-embedded tumor tissue (thickness, 4 µm) using a tissue microarray instrument (Beecher Instruments, Inc., Sun Prairie, WI, USA) and inserted into a novel acceptor block. The acceptor block underwent deparaffinization, using various concentrations of ethanol (70, 95 and 100%; Walter-CMP GmbH & Co. KG, Kiel, Germany) and rehydration. Endogenous peroxidase activity was blocked using methanol (with 0.3% hydrogen peroxide) (Walter-CMP GmbH & Co. KG) for 30 min. Antigen retrieval was preceded by a cooling time of 20 min at room temperature and incubation with primary antibodies for 30 min at room temperature ([Table II](#tII-ol-0-0-4588){ref-type="table"}). Catalyzed Signal Amplification System (Dako, Glostrup, Denmark) was used for CK1, 5/6, 8/18, 10, 14 and 19 immunohistochemistry, according to the manufacturer\'s protocol. The staining procedures for p53, p21, p27, p16, cyclin D1, epidermal growth factor receptor, mast/stem cell growth factor receptor (c-kit), B-cell lymphoma 6, α/β/γ-catenin, hypoxia inducible factor-1α (HIF-1α), glucose transporter 1 (GLUT1), carbonic anhydrase 9 (CAIX), caspase-3, heat shock protein (hsp) 70 and X-linked inhibitor of apoptosis protein (XIAP) were performed as previously described ([@b24-ol-0-0-4588],[@b25-ol-0-0-4588]). Antigen detection was performed by a standardised avidin-biotin complex method using anti-rabbit and anti-mouse biotinylated antibodies \[Dako REAL Detection Systems (LSAB+); catalog no. K5003; Dako\] and a Biotin-Blocking System (Ready-to-Use, catalog no. X0590; Dako). Diaminobenzidine (included in the p16 and EGFR kits; [Table II](#tII-ol-0-0-4588){ref-type="table"}) or LSAB 2 System-AP (Dako) was used for visualization, along with counterstaining with hematoxylin for 45 sec, followed by dehydration in alcohol and xylene (Walter-CMP GmbH & Co. KG). During TMA analysis and immunohistochemistry, negative (omission of the primary antibody) and positive controls were performed.

### Scoring of staining

Expression of CK1, 5/6, 8/18, 10, 14 and 19 was evaluated by the rate of positively stained cells in each core. The expression levels (%) were classified into three groups for CK19 (0%, no expression; 1--50%, moderate expression; \>50%, high expression) and into two groups for CK5/6, 8/18, 1, 10 and 14 (0%, no expression; ≥1%, positive expression). The mean percentage value of two cores from one tumor was calculated. Cytoplasmic expression of hsp70, caspase-3 and XIAP was graded as negative or positive (intermediate to strong expression), irrespective of the relative number of stained tumor cells. The remaning molcecules were assessed as follows: CAIX and p21/27/16 (\<1%, no expression; ≥1%, positive expression); HIF-1α and GLUT1 (\<1%, no expression; ≥1--4%, low expression; ≥5%, high expression); BCL-6, α-catenin, cyclin D1, c-kit and EGFR (0--15%, no expression; 16--50%, low expression; 85--100%, positive expression); β/γ-catenin (0--15%, no expression; 16--50%, low expression; 51--100%, high expression); p53 (\<5%, no expression; ≥5--50%, low expression; ≥50%, high expression). Moderate, intermediate, strong and high expressions were rendered as positive expression.

### Statistical analysis

Statistical analysis was performed using χ^2^ analysis. Biomathematical analysis of immunohistochemical data was evaluated using permutation analysis, which analyses information from protein-expression patterns of TMA data and identifies synergistic or antagonistic effects amongst all evaluated proteins ([@b26-ol-0-0-4588]). Botstein *et al* ([@b27-ol-0-0-4588]) describe this method as preserving the original physiological information of the tumor tissue and revealing the different compounds of the tumor samples to the smallest detail ([@b28-ol-0-0-4588],[@b29-ol-0-0-4588]). This combinatorial analysis calculates the ideal precedence of protein-expression coherence; therefore allowing the generation of an overview of differential regulation patterns in different tumor subgroups. A detailed description of this approach and its use in a clinical setting, using TMA data, have been previously described ([@b24-ol-0-0-4588],[@b29-ol-0-0-4588]). Statistical analysis was performed on R version 3.1.3 software ([www.r-project.org/](www.r-project.org/)), Fortran 95-based program 'TMAinspiration' ([complex-systems.uni-muenster.de/tma_inspiration.html](complex-systems.uni-muenster.de/tma_inspiration.html)) and SPSS version 21.0 software (IBM SPSS, Armonk, NY, USA)

Results
=======

### CK expression patterns and tumor localization

The expression (%) of the 6 CKs and other biomarkers in the SCC tumors are presented in [Table III](#tIII-ol-0-0-4588){ref-type="table"}. Representative images of immunohistochemical staining are presented in [Fig. 1](#f1-ol-0-0-4588){ref-type="fig"}.

Global, but not individual, CK expression in oral SCCs was significantly different between the anatomical localization of the tumor in the floor of the mouth and other localizations (floor of mouth vs. tongue, P=1.6×10^−4^; floor of mouth vs. other localizations, P=1.3×10^−4^; [Fig. 2A](#f2-ol-0-0-4588){ref-type="fig"}). SCCs located on the floor of the mouth revealed inverse regression lines in contrast to SCCs of other tumor subsites within the oral cavity, including the maxilla, tonsils and buccal region. Expression of CK8/18 and 19 was associated with SCCs of the floor of the mouth, whereas CK1, 10, 8/18 and 19 were equally expressed in all other subsites ([Fig. 2A](#f2-ol-0-0-4588){ref-type="fig"}).

### CK expression patterns and tumor grade

Significant differences could be observed in global CK expression patterns in association with tumor grade. Regression lines for grade 2 (G2) and 3 (G3) SCCs were similar, but regression lines for grade 1 (G1) SCCs exhibited an inverse behavior compared to G2 and G3 ([Fig. 2B](#f2-ol-0-0-4588){ref-type="fig"}).

G1 carcinomas revealed a statistically significant inverse association with G2 and G3 carcinomas concerning the expression of CK19 (P=4.1×10^−5^ and P=6.9×10^−5^, respectively). Expression of CK14 and 1 was predominantly observed in G3 SCCs (P=5.1×10^−3^ and P=0.03, respectively).

### CK expression patterns and cell cycle proteins and growth factors

Two patterns of cell cycle proteins expression were observed in association with CK expression. High-molecular weight CK14, 5/6, 1 and 10 exhibited similar regression lines compared with the regression lines exhibited by low-molecular weight CK8/18 and 19. In this molecular pattern p21, due to its extreme position in the regression approach, has the strongest impact in discriminating between the 6 CKs ([Fig. 2C](#f2-ol-0-0-4588){ref-type="fig"}). By contrast, EGFR does not play a major regulative role.

### CK expression patterns and factors involved in cell motility, apoptosis and cellular stress responses

Similar findings were observed in a second approach for factors involved in cell motility, apoptosis and cellular stress responses. As demonstrated in [Fig. 2C](#f2-ol-0-0-4588){ref-type="fig"}, CK14, 5/6, 1 and 10 revealed a contrasting expression compared with CK8/18 and 19. Comparable results were observed for c-kit, α/β/γ-catenin, HIF-1α, GLUT1, CAIX, caspase-3, hsp 70 and XIAP ([Fig. 2D](#f2-ol-0-0-4588){ref-type="fig"}). In this second pattern, the discriminating role was primarily performed by γ-catenin and hsp 70.

Discussion
==========

SCC of the oral cavity is associated with a variety of risk factors, including smoking, alcohol abuse, tobacco chewing, oral hygiene and human papilloma virus (HPV) infection ([@b30-ol-0-0-4588]--[@b34-ol-0-0-4588]). The current treatment protocols are based on a combination of surgery and radio/chemotherapy ([@b35-ol-0-0-4588],[@b36-ol-0-0-4588]). Despite these complex, multidisciplinary treatment regimens, the long term results are unsatisfactory ([@b1-ol-0-0-4588],[@b37-ol-0-0-4588]), the reasons for which are unclear. The underlying biology of SCCs remains poorly understood, and discerning the distinct molecular mechanisms underlying SCC may lead to improvements in treatment strategies.

CKs are the major intermediate filaments of squamous epithelium ([@b38-ol-0-0-4588],[@b39-ol-0-0-4588]), and in different organ systems it has been demonstrated that alterations in CK expression patterns leads to the altered expression of numerous genes and proteins ([@b9-ol-0-0-4588]--[@b11-ol-0-0-4588],[@b40-ol-0-0-4588]).

The present study demonstrates that previously described ([@b9-ol-0-0-4588],[@b10-ol-0-0-4588]) prognostically relevant cytokeratin expression patterns are associated with different expression patterns of crucial cellular proteins. Low-molecular weight CK8/18 and 19 expression had opposing patterns to high-molecular weight CK1, 5/6, 10 and 14 with biomarkers involving cell cycle regulation (p21), hypoxic stress (HIF-1α and CAIX) or cellular adhesion (α/γ-catenin). This indicates that CK8/18 and 19 are expressed in poorly-differentiated hypoxic SCC with a higher degree of cell cycle deregulation, whereas CK1, 5/6, 10 and 14 appear to be expressed in well-differentiated cancers with lower hypoxia and cell cycle deregulation. These results are similar to the general observation that low-molecular weight CK8/18 and 19 cytokeratins, whose expression is a hallmark of glandular tissues, are not physiologically expressed in normal squamous epithelium, but may be expressed during carcinogenesis ([@b11-ol-0-0-4588],[@b12-ol-0-0-4588],[@b41-ol-0-0-4588]).

These results are similar to previous studies regarding the prognostic significance of these proteins ([@b9-ol-0-0-4588],[@b10-ol-0-0-4588],[@b19-ol-0-0-4588],[@b21-ol-0-0-4588]). However, the interpretation of these findings is challenging, since it cannot be excluded that these alterations in expression of CKs and the chosen biomarkers are a reflection of tumor progression. By contrast, the present results may allow an alternative interpretation; in invasive breast cancer it was previously demonstrated that the expression of distinct high-molecular weight CKs defines a subgroup of poorly-differentiated breast cancer, representing a unique, independent pathway associated with poor prognosis, which has different responses to various treatment modalities ([@b42-ol-0-0-4588],[@b43-ol-0-0-4588]). Therefore, the present results may be as a result of the existence of different pathways in the pathogenesis of oral SCCs. At present, two pathways characterized by the differential expression of CKs may be distinguished in the present study. In various other tumor entities, such parallel, independent pathogenetic pathways have been reported for colorectal cancer, ovarian cancer and SCCs of the female genital tract, including the vulva and cervix ([@b24-ol-0-0-4588],[@b44-ol-0-0-4588]--[@b46-ol-0-0-4588]).

In addition, the present authors consider that the results support the hypothesis that SCCs of the oral cavity may not be regarded as a homogeneous entity. In the present study, global expression patterns of high- and low-molecular weight CKs exhibit clear differences between G1 and G2/3 SCCs. It may be argued that the alteration in CK expression has been interpreted as a result of tumor dedifferentiation. However, the present authors hypothesize that this may not be true for several reasons. The expression of CK8/18 and 19 has been described in epithelial precursor lesions of oral SCC ([@b10-ol-0-0-4588]), and therefore does not support the hypothesis that CK8/18 and 19 expression is a late phenomena in carcinogenesis after invasion has occurred. It is also widely accepted that CK expression patterns appear to be highly conserved during tumor progression ([@b8-ol-0-0-4588]). As a consequence, the existence of CK8/18 and/or 19-positive oral SCC raises fundamental controversies concerning their formal pathogenesis ([@b9-ol-0-0-4588],[@b10-ol-0-0-4588],[@b12-ol-0-0-4588],[@b41-ol-0-0-4588]). These carcinomas appear to represent an independent pathway rather than being the endstage of a stepwise dedifferentiation of CK8/18/19 negative SCCs. Therefore, it may be postulated that there is a low- and high-grade pathway. A similar concept has also been proposed for squamous intraepithelial neoplasms in the cervix and the vulva ([@b47-ol-0-0-4588],[@b48-ol-0-0-4588]), which is associated with various HPV subtypes ([@b44-ol-0-0-4588]).

The oral cavity is a highly complex anatomical region, emerging from various branchial arches that are associated with an aggregation of mesenchyme, ectoderm and endoderm ([@b49-ol-0-0-4588]--[@b51-ol-0-0-4588]); however, to what extent tumor localization has an effect on tumor biology and prognosis remains to be demonstrated. The present results reveal that differences appear to exist between SCCs on the floor of the mouth and SCCs of other anatomical subsites within the oral cavity, as observed by previous studies ([@b5-ol-0-0-4588],[@b21-ol-0-0-4588],[@b52-ol-0-0-4588],[@b53-ol-0-0-4588]). In the present study, SCCs of the floor of the mouth had an increased expressed of CK8/18 and 19. The number of tumors investigated in the present study was too small to allow for a definite conclusion; however the present results reveal that complex interactions appear to exist between the expression of CKs and other major cellular proteins, as well as tumor grade and anatomical sublocalization of SCCs of the oral cavity.

In summary, the present study analyzed low- and high-molecular weight CK expression in association with the expression of various other major cellular proteins using a sophisticated biomathematical algorithm in a series of 193 SCCs of the oral cavity. The present study provided evidence of the existence of two pathogenetic pathways characterized by the expression of low- and high-molecular weight CKs in oral SCC. These results provide evidence for additional investigation concerning the pathways identified and provide improved understanding of oral tumor biology.

![Representative samples of positive immunohistochemical staining with CK antibodies in oral squamous cell carcinoma. (A and B) CK10, (C and D) CK8/18 and (E and F) CK19 (magnification, ×10). CK, cytokeratin.](ol-12-01-0107-g00){#f1-ol-0-0-4588}

![Regression curves of the evaluated tumor samples examined by permutation analysis. (A) Oral tumor samples analyzed according to their localization and CK expression profile. (B) Tumor samples analyzed according to their histopathological grading and CK expression profile. (C) CK expression analyzed according to cell cycle and growth control regulation proteins. (D) CK expression analyzed according to hypoxic stress and cellular adhesion proteins. CK, cytokeratin; HIF-1α, hypoxia inducible factor-1α; GLUT1, glucose transporter 1; XIAP, X-linked inhibitor of apoptosis protein; CAIX, carbonic anhydrase 9; Hsp, heat shock protein; C-kit, mast/stem cell growth factor receptor; BCL-6, B-cell lymphoma-6; EGFR, epidermal growth factor receptor.](ol-12-01-0107-g01){#f2-ol-0-0-4588}

###### 

Clinicopathological characteristics of 193 patients with oral squamous cell carcinoma.

  Characteristic            Value
  ------------------------- --------
  Age at diagnosis, years   
    Mean                      59
    Range                   31--90
  Gender                    
    Female                    39
    Male                    154
  Tumor stage               
    T1                        96
    T2                        82
    T3-T4                     15
  Lymph node                
    Negative                136
    Positive                  57
  Tumor grade               
    G1                        44
    G2                      126
    G3                        23
  Disease recurrence        
    Positive                  66
    Negative                127
  Localization              
    Floor of mouth            76
    Tongue                    49
    Other                     68

###### 

Primary antibodies used for immunohistochemistry in the present study.

  Antibody    Supplier          Catalog no.          Clone             Mono/polyclonal   Species   Dilution   Antigen retrieval
  ----------- ----------------- -------------------- ----------------- ----------------- --------- ---------- -----------------------------------------
  p21         Merck Millipore   05--655              CP74              Mono              Mouse     1:500      Citrate buffer (pH6)
  p27         BD TL             610241               57/Kip1/p27       Mono              Mouse     1:1,000    Citrate buffer (pH6)
  p53         Dako              M7001                DO-7              Mono              Mouse     1:100      EDTA (pH8)
  HIF-1α      BD TL             610958               54/HIF-1α         Mono              Mouse     1:50       EDTA (pH8)
  GLUT1       Dako              M7211                Clone A 35        Mono              Mouse     1:40       EDTA (pH8)
  CAIX        Abcam             ab128883             --                Poly              Rabbit    1:1,000    Citrate buffer (pH6)
  XIAP        BD TL             610716               28/hILP/XIAP      Mono              Mouse     1:50       Citrate buffer (pH6)
  Hsp 70      Invitrogen        33--3800             MB-H1             Mono              Mouse     1:40       Citrate buffer (pH6)
  α-catenin   BD TL             610194               5/a-catenin       Mono              Mouse     1:250      EDTA (pH8)
  β-catenin   BD TL             610153               14/beta-Catenin   Mono              Mouse     1:1,000    EDTA (pH8)
  γ-catenin   BD TL             610253               15/γ-catenin      Mono              Mouse     1:1,500    EDTA (pH8)
  BCL-6       Dako              M7211                PG-B6p            Mono              Mouse     1:50       Citrate buffer (pH6)
  Caspase-3   Invitrogen        35--1600Z            43191             Mono              Mouse     1:100      Citrate buffer (pH6)
  C-kit       Dako              A4502                --                Poly              Rabbit    1:200      Citrate buffer (pH6)
  CK1         Novocastra        NCL-Ck1              34βB4             Mono              Mouse     1:150      Citrate buffer (pH6)
  CK5/6       Dako              M7237                D5/16 B4          Mono              Mouse     1:80       Autoclave (10 min)
  CK10        Dako              M7002                DE-K10            Mono              Mouse     1:400      Citrate buffer (pH6)
  CK14        Dianova GmbH      DLN-06600            LL002             Mono              Mouse     1:50       Citrate buffer (pH6)
  CK8/18      Dianova GmbH      DLN-08110            K8.8/DC10         Mono              Mouse     1:40       Autoclave (10 min), citrate buffer (pH)
  CK19        Dianova GmbH      DLN-08330            KS19.1            Mono              Mouse     1:80       Citrate buffer (pH6)
  Cyclin D1   Novocastra        NCL-L-cyclin D1-GM   P2D11F11          Mono              Mouse     1:20       EDTA (pH8)
  EGFR        Dako              K1492                pharmDX kit       Mono              Mouse     --         --
  p16         CINtec            9517                 E6H4              Mono              Mouse                Citrate buffer (pH6)

Merck Millipore, Darmstadt, Germany; BD TL, BD Transduction Laboratories™, BD Biosciences, Frankling Lakes, NJ, USA; Dako, Glostrup, Denmark; Invitrogen™, Thermo Fisher Scientific, Inc., Waltham, MA, USA; Abcam, Cambridge, UK; Novocastra™, Leica Biosystems GmbH, Nussloch, Germany; Dianova GmbH, Hamburg, Germany; CINtec^®^, Roche AG, Basel Switzerland. EDTA and citrate buffers were purchased from Dako and Zytomed Systems GmbH (Berlin, Germany), respectively. CK, cytokeratin; HIF-1α, hypoxia inducible factor-1α; GLUT1, glucose transporter 1; XIAP, X-linked inhibitor of apoptosis protein; CAIX, carbonic anhydrase 9; Hsp, heat shock protein; C-kit, mast/stem cell growth factor receptor; BCL-6, B-cell lymphoma-6; EGFR, epidermal growth factor receptor.

###### 

Expression of CKs and other biomarkers in 193 samples of oral squamous cell carcinoma.

              Expression, % of tumors   
  ----------- ------------------------- --------
  CK1         53.9                        0.5
  CK5/6         1.7                       98.3
  CK8/18      33.3                        66.7
  CK10        62.8                        37.2
  CK14          2.6                       97.4
  CK19        59.9                        40.1
  α-catenin   34.6                        65.4
  β-catenin   15.8                        84.2
  γ-catenin   35.0                        65.0
  GLUT1         8.5                       91.5
  Caspase-3   74.2                        25.8
  XIAP        80.5                        19.5
  CAIX        73.4                        26.6
  Hsp 70      89.3                        10.7
  C-kit       86.4                        13.6
  p16         79.4                        20.6
  p21         28.8                        71.2
  p27         79.8                        20.2
  p53           0.0                     100.0
  BCL-6       78.7                        21.3
  EGFR        24.9                        75.1
  Cyclin D1   50.6                        49.4
  HIF-1α      42.2                        57.8

CK, cytokeratin; GLUT1, glucose transporter 1; XIAP, X-linked inhibitor of apoptosis protein; CAIX, carbonic anhydrase 9; Hsp, heat shock protein; C-kit, mast/stem cell growth factor receptor; BCL-6, B-cell lymphoma-6; EGFR, epidermal growth factor receptor; HIF-1α, hypoxia inducible factor-1α.
